Wedbush Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on IDEAYA Biosciences but lowers the price target from $54 to $52.
September 24, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on IDEAYA Biosciences but lowers the price target from $54 to $52.
The Outperform rating suggests a positive outlook, but the lowered price target indicates a slight reduction in expected upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100